SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

ZERBAXA

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already marketed since 2014. The most recent label expansion (pediatric HABP/VABP) was approved in May 2026. Patent protection extends to approximately February 2036 per FDA-listed patents.
Why 3/10
ZERBAXA is an already-approved, marketed drug with no pending PDUFA date, Advisory Committee, or pivotal readout in the next ~12 months. The most recent catalyst (pediatric label expansion) was completed in May 2026. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5, and ZERBAXA's small contribution to Merck's $65B+ revenue base anchors it at the low end of that range.
Actionable Insight NEUTRAL

ZERBAXA has no upcoming PDUFA dates or pivotal readouts in the next 12 months. Investors should watch quarterly Merck earnings reports for ZERBAXA sales trends, particularly whether the May 2026 pediatric label expansion drives measurable revenue acceleration. The key competitive dynamic to monitor is how ZERBAXA fares against Avycaz and Vabomere in the hospital antibiotic market, especially for Pseudomonas coverage. For MRK investors, ZERBAXA is a minor product; the stock's primary drivers remain Keytruda, Gardasil, and the broader pipeline.

Price Chart

Loading chart...

Executive Summary

ZERBAXA (ceftolozane/tazobactam) is a hospital-use IV antibiotic from Merck & Co., Inc. (NYSE: MRK) that targets multidrug-resistant gram-negative infections, including Pseudomonas aeruginosa. First approved by the FDA in December 2014 for complicated intra-abdominal and urinary tract infections, it later added hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in adults. The FDA approved a pediatric label expansion in May 2026. With estimated 2024 sales of roughly $252M, ZERBAXA is a small but growing product within Merck's massive $65B+ pharmaceutical portfolio. Patent protection runs to approximately February 2036. No upcoming binary catalysts are scheduled, making this a steady commercial-stage asset rather than a near-term stock-moving event.

How It Works

ZERBAXA is a combination of two drugs in one IV infusion: ceftolozane (a cephalosporin antibiotic that kills certain gram-negative bacteria by disrupting their cell walls) and tazobactam (a beta-lactamase inhibitor that prevents bacteria from destroying ceftolozane). It is designed to treat multidrug-resistant infections, especially tough Pseudomonas aeruginosa and other hard-to-kill gram-negative bacteria in hospitalized patients.

Trial Status

ZERBAXA was initially FDA-approved in December 2014 for complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A pivotal Phase 3 trial (Trial 3) comparing ZERBAXA 3g every 8 hours against meropenem in 720 patients with hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) met its primary non-inferiority endpoint, leading to FDA approval for that indication in adults. In May 2026, the FDA expanded the label to include pediatric patients (at least 32 weeks gestational age) for HABP/VABP and broadened the pediatric age range for cIAI and cUTI based on an open-label PK/safety study (NCT04223752).

The Two-Sided Case

▲ Bull Case4
ZERBAXA is a well-established hospital antibiotic with a growing addressable market as antimicrobial resistance increases, particularly against multidrug-resistant Pseudomonas aeruginosa where it is considered by some clinicians as preferred over alternatives like Avycaz (ceftazidime/avibactam).
The May 2026 pediatric label expansion opens a new patient population for HABP/VABP, cIAI, and cUTI, potentially supporting continued revenue growth from the estimated $252M in 2024 sales.
Patent protection through approximately February 2036 provides a long exclusivity runway with no near-term generic threat.
Merck's massive commercial infrastructure and hospital sales force can maximize ZERBAXA's reach across existing and new indications.
▼ Bear Case4
ZERBAXA is a relatively small product for Merck (roughly $252M in 2024 sales versus Merck's $65B+ total revenue), so even strong sales growth would have a negligible impact on the stock.
The hospital antibiotic market is competitive, with branded rivals including Avycaz (ceftazidime/avibactam), Vabomere (meropenem/vaborbactam), and newer entrants, all targeting similar resistant gram-negative infections.
As an already-approved, marketed drug with no pending regulatory catalysts, ZERBAXA lacks the binary event that typically drives significant share-price moves for a developer.
Antibiotic stewardship programs and formulary restrictions may limit utilization growth despite label expansions.

Upcoming Catalysts

  • No upcoming PDUFA dates or pivotal readouts identified for ZERBAXA in the next 12 months. The drug is already approved for its core indications and the most recent label expansion (pediatric) was completed in May 2026.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 14

Hover a chip for the title
1 en.wikipedia.org2 drugs.com3 merck.com4 fda.gov5 accessdata.fda.gov6 accessdata.fda.gov7 assyro.com8 pharmacompass.com9 idstewardship.com10 drugpatentwatch.com11 merck.com12 mattheneus.com13 hellopharmacist.com14 cliffbio.com